Home » Stocks » VCEL

Vericel Corporation (VCEL)

Stock Price: $51.64 USD -1.60 (-3.01%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
Market Cap 2.39B
Revenue (ttm) 132.07M
Net Income (ttm) 4.28M
Shares Out 45.98M
EPS (ttm) 0.09
PE Ratio 580.22
Forward PE 909.09
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $51.64
Previous Close $53.24
Change ($) -1.60
Change (%) -3.01%
Day's Open 53.00
Day's Range 51.25 - 53.18
Day's Volume 225,555
52-Week Range 14.45 - 68.94

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

CAMBRIDGE, Mass., July 21, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following ...

5 days ago - GlobeNewsWire

Restoring cartilage in sports medicine and rebuilding skin after severe burns gave this small-cap big upside

1 week ago - Zacks Investment Research

NEW YORK, July 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vericel Corporation ("Vericel" or the "Company") (NASDAQ: VCEL).  Such investors are advised to co...

1 week ago - PRNewsWire

CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Cola...

2 weeks ago - GlobeNewsWire

The FDA says "no" to the company's NexoBrid -- for now.

3 weeks ago - The Motley Fool

Shares of MediWound (NASDAQ: MDWD) and its development partner, Vericel Corporation (NASDAQ: VCEL), are trading lower after MediWound received a Complete Response Letter from the FDA for its NexoBrid Bi...

Other stocks mentioned: MDWD
3 weeks ago - Benzinga

Vericel Corporation's (NASDAQ:VCEL) development partner, MediWound Ltd (NASDAQ:MDWD), received a complete response letter from FDA regarding the NexoBrid application seeking approval for eschar removal ...

Other stocks mentioned: MDWD
3 weeks ago - Benzinga

CAMBRIDGE, Mass., June 29, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that its devel...

3 weeks ago - GlobeNewsWire

CAMBRIDGE, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Cola...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointmen...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colan...

2 months ago - GlobeNewsWire

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -16.67% and 8.24%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Vericel (NASDAQ:VCEL) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share rose 30.00% year over year to ($0.07), which missed the estimate of ($0.04).

2 months ago - Benzinga

First Quarter Total Net Revenue Increased 30% to $34.6 Million

2 months ago - GlobeNewsWire

Vericel Corporation (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

CAMBRIDGE, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following...

3 months ago - GlobeNewsWire

CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Col...

3 months ago - GlobeNewsWire

The company will be a component of a well-known small-cap stock index.

4 months ago - The Motley Fool

NEW YORK, March 17, 2021 /PRNewswire/ -- Vericel Corp. (NASD:VCEL) will replace QEP Resources Inc. (NYSE:QEP) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, March 22. S&P 5...

Other stocks mentioned: QEP
4 months ago - PRNewsWire

In the latest trading session, Vericel Corporation (VCEL) closed at $42.92, marking a -0.26% move from the previous day.

4 months ago - Zacks Investment Research

CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Col...

4 months ago - GlobeNewsWire

Sometimes valuation metrics can be deceiving.

Other stocks mentioned: HALO
4 months ago - The Motley Fool

Vericel Corporation (VCEL) delivered earnings and revenue surprises of 19.05% and 0.40%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Shares of Vericel (NASDAQ:VCEL) rose 1.0% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 25.00% year over year to $0.25, which beat the estimat...

5 months ago - Benzinga

CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Cola...

5 months ago - GlobeNewsWire

In the latest trading session, Vericel Corporation (VCEL) closed at $51.15, marking a -0.04% move from the previous day.

5 months ago - Zacks Investment Research

Vericel Corporation (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Is (VCEL) Outperforming Other Medical Stocks This Year?

5 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Cola...

5 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that its Board...

5 months ago - GlobeNewsWire

Vericel Corporation (VCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

5 months ago - Zacks Investment Research

Bull of the Day: Vericel (VCEL)

5 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, announced the appointment of J...

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Cola...

6 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that UnitedHea...

6 months ago - GlobeNewsWire

Vericel is a high growth, disruptive biotechnology company with annual sales increasing at a 30% rate prior to the COVID-19 pandemic. The Company's tissue repair and restoration products are proprietary...

6 months ago - Seeking Alpha

The company's earnings are expected to increase exponentially in 2021

6 months ago - GuruFocus

CAMBRIDGE, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Cola...

7 months ago - GlobeNewsWire

Vericel is a low-risk, high-quality small biotech with high growth potential. The business is already profitable with 70% gross profit margin and no debt on the balance sheet.

7 months ago - Seeking Alpha

Vericel Corporation (VCEL) CEO Nick Colangelo on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Total Net Revenues of $32.3 Million and Net Income of $3.6 Million

8 months ago - GlobeNewsWire

Technology won't always be on top. There's a bunch of budding industries that could prove to be winners over the next 5 years.

Other stocks mentioned: EXAS, INMD, QQQ, XLK
8 months ago - Zacks Investment Research

Bull of the Day: Vericel (VCEL)

8 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced presentations ...

8 months ago - GlobeNewsWire

Vericel Corp (VCEL) has been struggling lately, but the selling pressure may be coming to an end soon.

8 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following ...

9 months ago - GlobeNewsWire

Double-Digit Revenue, Implant and Biopsy Growth for MACI in the Quarter and Record Monthly Biopsies in September

9 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Oct. 09, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, will host a virtual Analyst an...

9 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the recently submitted ...

10 months ago - GlobeNewsWire

About VCEL

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-de... [Read more...]

Industry
Biotechnology
IPO Date
Feb 4, 1997
CEO
Dominick Colangelo
Employees
273
Stock Exchange
NASDAQ
Ticker Symbol
VCEL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for Vericel stock is "Buy." The 12-month stock price forecast is 65.71, which is an increase of 27.25% from the latest price.

Price Target
$65.71
(27.25% upside)
Analyst Consensus: Buy